93 results on '"Elisei, Rossella"'
Search Results
2. Diagnostic Applications of Nuclear Medicine: Thyroid Tumors
- Author
-
Elisei, Rossella, Agate, Laura, Mazzarri, Sara, Bottici, Valeria, Guidoccio, Federica, Molinaro, Eleonora, Boni, Giuseppe, Ferdeghini, Marco, Mariani, Giuliano, Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor
- Published
- 2022
- Full Text
- View/download PDF
3. Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules.
- Author
-
Gambale, Carla, Rocha, José Vicente, Prete, Alessandro, Minaldi, Elisa, Elisei, Rossella, and Matrone, Antonio
- Subjects
THYROID nodules ,THYROID cancer ,ADULTS ,PHYSICIANS ,ULTRASONIC imaging - Abstract
Thyroid nodules in pediatric patients are less common than in adults but show a higher malignancy rate. Accordingly, the management of thyroid nodules in pediatric patients is more complex the younger the patient is, needing careful evaluation by physicians. In adult patients, specific ultrasound (US) features have been associated with an increased risk of malignancy (ROM) in thyroid nodules. Moreover, several US risk stratification systems (RSSs) combining the US features of the nodule were built to define the ROM. RSSs are developed for the adult population and their use has not been fully validated in pediatric patients. This study aimed to evaluate the available data about US features of thyroid nodules in pediatric patients and to provide a summary of the evidence regarding the performance of RSS in predicting malignancy. Moreover, insights into the management of thyroid nodules in pediatric patients will be provided. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
- Author
-
Brose, Marcia S., Capdevila, Jaume, Elisei, Rossella, Bastholt, Lars, Führer-Sakel, Dagmar, Leboulleux, Sophie, Iwao Sugitani, Taylor, Matthew H., Zhuoying Wang, Wirth, Lori J., Worden, Francis P., Bernard, John, Caferra, Paolo, Colzani, Raffaella M., Shiguang Liu, and Schlumberger, Martin
- Subjects
THYROID cancer ,CLINICAL trials ,IODINE isotopes ,TERMINATION of treatment ,PROTEIN-tyrosine kinases ,PROGRESSION-free survival - Abstract
The VERIFY study aimed to determine the efficacy of vandetanib in patients with differentiated thyroid cancer (DTC) that is either locally advanced or metastatic and refractory to radioiodine (RAI) therapy. Specifically, VERIFY is a randomized, double-blind, multicenter phase III trial aimed to determine the efficacy and safety of vandetanib in tyrosine kinase inhibitor-naive patients with locally advanced or metastatic RAI-refractory DTC with documented progression (NCT01876784). Patients were randomized 1:1 to vandetanib or placebo. The primary endpoint was progression-free survival (PFS). Secondary endpoints included best objective response rate, overall survival (OS), safety, and tolerability. Patients continued to receive randomized treatment until disease progression or for as long as they were receiving clinical benefit unless criteria for treatment discontinuation were met. Following randomization, 117 patients received vandetanib, and 118 patients received a placebo. Median PFS was 10.0 months in the vandetanib group and 5.7 months in the placebo group (hazard ratio: 0.75; 95% CI: 0.55–1.03; P = 0.080). OS was not significantly different between treatment arms. Common Terminology Criteria for Adverse Events (CTCAE) of grade ≥3 were reported in 55.6% of patients in the vandetanib arm and 25.4% in the placebo arm. Thirty-three deaths (28.2%; one related to study treatment) occurred in the vandetanib arm compared with 16 deaths (13.6%; two related to treatment) in the placebo arm. No statistically significant improvement was observed in PFS in treatment versus placebo in patients with locally advanced or metastatic, RAI-refractory DTC. Moreover, active treatment was associated with more adverse events and more deaths than placebo, though the difference in OS was not statistically significant. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Thyroid cancer and COVID-19: experience at one single thyroid disease referral center
- Author
-
Prete, Alessandro, Falcone, Marco, Bottici, Valeria, Giani, Carlotta, Tiseo, Giusy, Agate, Laura, Matrone, Antonio, Cappagli, Virginia, Valerio, Laura, Lorusso, Loredana, Minaldi, Elisa, Molinaro, Eleonora, and Elisei, Rossella
- Published
- 2021
- Full Text
- View/download PDF
6. Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer.
- Author
-
Matrone, Antonio, Prete, Alessandro, Gambale, Carla, and Elisei, Rossella
- Subjects
MEDULLARY thyroid carcinoma ,SOMATIC mutation ,THYROID cancer ,BRAF genes - Abstract
RET somatic mutation analysis in sporadic MTC should be guided by postoperative evaluation results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Diagnostic Applications of Nuclear Medicine: Thyroid Tumors
- Author
-
Elisei, Rossella, Agate, Laura, Mazzarri, Sara, Bottici, Valeria, Guidoccio, Federica, Molinaro, Eleonora, Boni, Giuseppe, Ferdeghini, Marco, Mariani, Giuliano, Strauss, H. William, editor, Mariani, Giuliano, editor, Volterrani, Duccio, editor, and Larson, Steven M., editor
- Published
- 2017
- Full Text
- View/download PDF
8. BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.
- Author
-
Matrone, Antonio, Citro, Fabrizia, Gambale, Carla, Prete, Alessandro, Minaldi, Elisa, Ciampi, Raffaele, Ramone, Teresa, Materazzi, Gabriele, Torregrossa, Liborio, and Elisei, Rossella
- Subjects
THYROID cancer ,LITERATURE reviews ,BRAF genes ,NUCLEOTIDE sequencing ,GENETIC mutation ,PAPILLARY carcinoma - Abstract
Background: Thyroid carcinoma (TC) is the most common endocrine cancer, with papillary thyroid carcinoma (PTC) being the most common subtype. BRAF and RAS oncogene were characterized as the most frequently altered genes in PTC, with a strong association between genotype and histotype. The most common mutation in BRAF gene is V600E and is prevalent in classic and aggressive variants of PTC, while BRAF K601E mutation is the most common among the other rare BRAF mutations. BRAF K601E mutated thyroid carcinomas are usually characterized by low aggressiveness, except for anecdotal cases of poorly differentiated TC. Case presentation: We described a case of oncocytic carcinoma of the thyroid (OCA) with an aggressive clinical course, including widespread metastasis and resistance to radioiodine treatment. Molecular analysis revealed the exclusive presence of the BRAF K601E mutation in both primary tumor and metastatic lesions. Accordingly, a revision of the literature about aggressive TC cases carrying BRAF K601E mutation was performed. Conclusion: Although rare, this case emphasizes the relevance of considering BRAF K601E mutation in advanced non-PTC thyroid carcinomas, since it can be considered an actionable mutation for target therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma.
- Author
-
Sgrò, Daniele, Brancatella, Alessandro, Greco, Giuseppe, Torregrossa, Liborio, Piaggi, Paolo, Viola, Nicola, Rago, Teresa, Basolo, Fulvio, Giannini, Riccardo, Materazzi, Gabriele, Elisei, Rossella, Santini, Ferruccio, and Latrofa, Francesco
- Subjects
CYTOLOGY ,THYROID nodules ,THYROID cancer - Abstract
Context: Prognosis is excellent for papillary thyroid carcinoma (PTC), noninvasive follicular thyroid neoplasia with papillary-like nuclear features (NIFT-P), and follicular thyroid carcinoma (FTC) but is poor for poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC). Among PTCs, the prognosis is more favorable for follicular (FV-PTC) and classic (CV-PTC) than for tall cell (TCV-PTC), and solid (SV-PTC) variants. Objective: To associate histotypes and variants of thyroid carcinoma with ultrasound and cytological features. Methods: Histology of 1018 benign tumors and 514 PTC (249 CV, 167 FV, 49 TC, 34 SV, and 15 other variants), 52 NIFT-P, 50 FTC, 11 PDTC, and 3 ATC was correlated with fine-needle aspiration biopsy categories (Italian classification: TIR1, TIR2, TIR3A, TIR3B, TIR4, and TIR5) and ultrasound features at the Endocrinology Unit, University Hospital of Pisa. In total, 1117 patients with thyroid nodule(s) who underwent thyroidectomy were included. Results: Of PTC, 36.3% had indeterminate cytology (TIR3A or TIR3B), 56.6% were suspicious for malignancy or malignant (TIR4 or TIR5); 84.0% FTC and 69.3% NIFT-P were TIR3A or TIR3B; 72.5% FV-PTC and 73.6% SV-PTC were TIR3A or TIR3B; 79.9% CV-PTC and 95.9% TCV-PTC were TIR4 or TIR5. The association of a hypoechoic pattern, irregular margins, and no microcalcifications was more frequent in TCV-PTC than in CV-PTC (P = .02, positive predictive value = 38.9%; negative predictive value = 85.5%). Conclusion: At cytology, most FTC, NIFT-P, FV-PTC, and SV-PTC were indeterminate, most CV-PTC and TCV-PTC were suspicious for malignancy or malignant. Ultrasound can be helpful in ruling out TCV-PTC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib.
- Author
-
Sgrò, Daniele, Rossi, Piercarlo, Piaggi, Paolo, Brancatella, Alessandro, Lorusso, Loredana, Bottici, Valeria, Molinaro, Eleonora, Latrofa, Francesco, Elisei, Rossella, and Agate, Laura
- Subjects
THYROID cancer ,CANCER patients ,AUTOANTIBODIES ,THYROGLOBULIN ,POSTOPERATIVE care ,BIOMARKERS ,THYROIDECTOMY - Abstract
Context Serum thyroglobulin (Tg) is a highly sensitive and specific tumor marker, employed in post-operative management of patients with differentiated thyroid carcinomas. Tumor shrinkage of radioiodine-refractory thyroid cancer (RAIR-DTC) treated with multitarget kinase inhibitors as lenvatinib, expressed according to the Response Evaluation Criteria in Solid Tumors (RECIST), is also associated with a drastic reduction of Tg levels. However, interference caused by circulating thyroglobulin autoantibodies (TgAb) represents the main limitation in the clinical use of Tg. Objective To evaluate if in RAIR-DTC TgAb could be considered a surrogate marker of Tg in monitoring response to treatment with lenvatinib. Design We retrospectively evaluated patients who had started lenvatinib and correlated serum Tg and TgAb with the radiological response across visits. Setting University of Pisa, Italy. Patients We selected 9/97 RAIR-DTC patients with detectable TgAb. Intervention None. Main Outcome Measure(s) None. Results Tg values correlated neither with TgAb title nor with radiological response across visits. Greater decreases in TgAb titer correlated with favorable radiological response to lenvatinib after 1 month (Spearman's correlation = 0.74, P =.021) and 6 months (correlation = 0.61, P =.079). According to RECIST, patients with partial response showed a ∼10-fold greater decrease in TgAb compared to those with stable disease at 1 month (median TgAb decrease: −142 vs −14 IU/mL, P =.01) and those with progressive disease at 6 months (median TgAb decrease: −264 vs−24 IU/mL, P =.04). Conclusion TgAb evaluation may represent a reliable surrogate marker for Tg trend in evaluating response of RAIR-DTC to treatment with lenvatinib. A multicentric study would be useful to confirm our results. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors.
- Author
-
Matrone, Antonio, Gambale, Carla, Pieroni, Erica, De Napoli, Luigi, Torregrossa, Liborio, Materazzi, Gabriele, and Elisei, Rossella
- Subjects
ULTRASONIC imaging ,THYROID cancer - Abstract
Objective: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) is an encapsulated follicular variant of papillary thyroid carcinoma (PTC) with nonaggressive clinical behavior. However, since its diagnosis is exclusively possible after surgery, it represents a clinical challenge. Neck ultrasound (US) shows good sensitivity and specificity in suggesting malignancy in thyroid nodules. However, little information is available about its ability in identifying NIFT-P. Design: The aim of this study was to evaluate the US features of NIFT-P, comparing them with other follicular-patterned thyroid tumors, and to test the ability of the main US risk stratification system (RSS) in identifying NIFT-P. Methods: We retrospectively evaluated 403 consecutive patients submitted to thyroid surgery, with positive histology for at least 1 nodule being NIFT-P, follicular variant of PTC (FV-PTC), follicular thyroid carcinoma (FTC), or follicular adenoma (FA). Results: The US features of NIFT-P (n = 116), FV-PTC (n = 170), FTC (n = 76), and FA (n = 90) were reported. Follicular variant of PTC and FTC more frequently showed irregular margins, presence of calcifications, "taller than wide" shape, and the absence of halo compared with NIFT-P. Furthermore, FTC and also FA were larger and more frequently hypoechoic than NIFT-P. Most cases (77%) showed an indeterminate cytology. Regardless of the US RSS considered, NIFT-P and FA were less frequently classified in the high-suspicious category compared with FV-PTC and FTC. Conclusions: Ultrasound features of NIFT-P are frequently superimposable to those of nodules with low suspicion of malignancy. The NIFT-P is almost never classified in the high-suspicious category according to the main US RSS. Therefore, although the preoperative identification of NIFT-P remains a challenge, neck US can be integrated in the algorithm of management of nodules with indeterminate cytology, suggesting a possible conservative approach in those with low-suspicious features. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis.
- Author
-
Viola, Nicola, Agate, Laura, Caprio, Sonia, Lorusso, Loredana, Brancatella, Alessandro, Ricci, Debora, Sgrò, Daniele, Ugolini, Clara, Piaggi, Paolo, Vitti, Paolo, Elisei, Rossella, Santini, Ferruccio, and Latrofa, Francesco
- Subjects
AUTOANTIBODIES ,THYROID cancer ,CANCER prognosis ,AUTOIMMUNITY ,THYROIDITIS ,AUTOIMMUNE thyroiditis ,THYROID gland - Abstract
The relevance of thyroid autoimmunity to the prognosis of papillary thyroid carcinoma is still unsettled. We decided to investigate the impact of thyroid autoimmunity on the prognosis of papillary thyroid carcinoma and the handling of TgAbs. We evaluated the clinical course of a large group of patients according to the presence (PTC-LT) or absence (PTC) of lymphocytic thyroiditis at histology. We studied 194 consecutive patients with a diagnosis of PTC and treated them with total thyroidectomy plus
131 I ablation between 2007 and 2009. Median follow-up (with 25th-75th percentiles) was 84.0 (56.4-118.0) months. The remission criteria were: basal Tg < 0.2 ng/mL (or stimulated Tg: < 1), TgAbs < 8 IU/mL (otherwise 'decreasing TgAb trend', a decline of ≤20% in sequential TgAb measurements) and unremarkable imaging. PTC-LT and PTC patients had comparable treatment. TgAbs were detectable in 72.5% of PTC-LT and 16.5% of PTC patients. Time to remission was longer in the detectable than in the undetectable TgAb cohort (28.5 vs· 7.5 months (median); HR: 0.54, CI: 0.35-0.83, P = 0.005). When comparing PTC-LT to PTC patients, the difference was maintained in the detectable TgAb (29.3 vs 13.0 months; HR: 0.38, CI: 0.18-0.80; P = 0.01) but not in the undetectable TgAb cohort (7.7 vs 7.3 months; HR: 0.90, CI: 0.55-1.47; P = 0.68). Using the decreasing TgAb trend, the influence of detectable TgAbs on time to remission was abolished. Thyroid autoimmunity does not influence the prognosis of papillary thyroid carcinoma. A decreasing TgAb trend seems an appropriate criterion to establish the remission of papillary thyroid carcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
13. Thyroid Cancer in Ukraine After the Chernobyl Accident: Incidence, Pathology, Treatment, and Molecular Biology
- Author
-
Tronko, Mykola, Bogdanova, Tetyana, Likhtarev, Ilya, Komisarenko, Ihor, Kovalenko, Andriy, Markov, Valentyn, Tereshchenko, Valery, Voskoboynyk, Larysa, Zurnadzhy, Lyudmyla, Shpak, Victor, Gulak, Lyudmyla, Elisei, Rossella, Romei, Cristina, Pinchera, Aldo, Nakashima, Masahiro, editor, Takamura, Noboru, editor, Tsukasaki, Kunihiro, editor, Nagayama, Yuji, editor, and Yamashita, Shunichi, editor
- Published
- 2009
- Full Text
- View/download PDF
14. Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe.
- Author
-
Elisei, Rossella, Grande, Enrique, Kreissl, Michael C., Leboulleux, Sophie, Puri, Tarun, Fasnacht, Nicolas, and Capdevila, Jaume
- Subjects
THYROID cancer ,MEDULLARY thyroid carcinoma ,PATIENTS' attitudes ,PROTEIN-tyrosine kinases ,GENE fusion ,GENETIC testing - Abstract
The incidence of thyroid cancer is increasing worldwide with the disease burden in Europe second only to that in Asia. In the last several decades, molecular pathways central to the pathogenesis of thyroid cancer have revealed a spectrum of targetable kinases/kinase receptors and oncogenic drivers characteristic of each histologic subtype, such as differentiated thyroid cancer, including papillary, follicular, and medullary thyroid cancer. Oncogenic alterations identified include B-Raf proto-oncogene (BRAF) fusions and mutations, neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and rearranged during transfection (RET) receptor tyrosine kinase fusion and mutations. Multikinase inhibitors (MKIs) targeting RET in addition to multiple other kinases, such as sorafenib, lenvatinib and cabozantinib, have shown favourable activity in advanced radioiodine-refractory differentiated thyroid cancer or RET-altered medullary thyroid cancer; however, the clinical utility of MKI RET inhibition is limited by offtarget toxicity resulting in high rates of dose reduction and drug discontinuation. Newer and selective RET inhibitors, selpercatinib and pralsetinib, have demonstrated potent efficacy and favourable toxicity profiles in clinical trials in the treatment of RET-driven advanced thyroid cancer and are now a therapeutic option in some clinical settings. Importantly, the optimal benefits of available specific targeted treatments for advanced RET-driven thyroid cancer require genetic testing. Prior to the initiation of systemic therapy, and in treatment-naïve patients, RET inhibitors may be offered as first-line therapy if a RET alteration is found, supported by a multidisciplinary team approach. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.
- Author
-
Cristina Campopiano, Maria, Ghirri, Arianna, Prete, Alessandro, Lorusso, Loredana, Puleo, Luciana, Cappagli, Virginia, Agate, Laura, Bottici, Valeria, Brogioni, Sandra, Gambale, Carla, Minaldi, Elisa, Matrone, Antonio, Elisei, Rossella, and Molinaro, Eleonora
- Subjects
WATCHFUL waiting ,THYROID cancer ,PHYSICIANS ,DISEASE progression ,MEDICAL personnel ,THERAPEUTICS - Abstract
Currently, the differentiated thyroid cancer (DTC) management is shifted toward a tailored approach based on the estimated risks of recurrence and diseasespecific mortality. While the current recommendations on the management of metastatic and progressive DTC are clear and unambiguous, the management of slowly progressive or indeterminate disease varies according to different centers and different physicians. In this context, active surveillance (AS) becomes the main tool for clinicians, allowing them to plan a personalized therapeutic strategy, based on the risk of an unfavorable prognosis, and to avoid unnecessary treatment. This review analyzes the main possible scenarios in treated DTC patients who could take advantage of AS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma.
- Author
-
Minaldi, Elisa, Giani, Carlotta, Agate, Laura, Molinaro, Eleonora, and Elisei, Rossella
- Subjects
THYROID cancer ,THYROIDECTOMY ,IODINE isotopes ,CANCER relapse ,DISEASE relapse ,SURGERY ,THERAPEUTICS - Abstract
Background: Currently, surgery alone is the gold standard treatment for minimally invasive follicular thyroid cancer (mi-FTC). Case presentation: A case of a mi-FTC diagnosed in 1994 was treated with total thyroidectomy and radioiodine (RAI) ablation, according to the therapeutic algorithm used at that time. Nevertheless, he had a recurrence with distant metastasis after 24 years from the initial treatment. Conclusion: Total thyroidectomy and RAI ablation might have delayed the development of distant metastasis but they were not sufficient to avoid disease recurrence. Certainly, remnant ablation simplified the follow-up and the monitoring of serum thyroglobulin allowed the early detection of the biochemical recurrence, but didn't change the outcome of the disease. Moreover, because of this early detection the patient was exposed to useless biochemical and imaging examinations. The aim of this report is to discuss the pros and cons of an aggressive treatment of a patient with mi-FTC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management?
- Author
-
Matrone, Antonio, Basolo, Alessio, Santini, Ferruccio, and Elisei, Rossella
- Subjects
THYROID cancer ,WATCHFUL waiting ,OBESITY ,SYMPTOMS ,BODY weight - Abstract
Several studies have focused on the relationship between obesity and differentiated thyroid carcinoma (DTC), particularly papillary histotype (PTC). However, the association of obesity with both incidence and aggressiveness of PTC is still incompletely understood. We reviewed the mechanisms underlying the cross talk between obesity and thyroid carcinomas and described the most recent evidence evaluating the effect of obesity on the development of PTC, as well as the impact of excessive body weight on the clinicopathologic features and outcome of this type of cancer. Available evidence suggests that excessive body weight is linked with a higher risk of getting PTC, while its impact on the aggressiveness of the disease, if present, is still not clear. Therefore, while attention should be paid to discover thyroid cancer in patients with obesity earlier, once diagnosed it should be managed following a conventional workup as in normal weight patients, based on the clinical presentation of the disease and including active surveillance if appropriate, as recommended by referral guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma.
- Author
-
Macerola, Elisabetta, Proietti, Agnese, Poma, Anello Marcello, Vignali, Paola, Sparavelli, Rebecca, Ginori, Alessandro, Basolo, Alessio, Elisei, Rossella, Santini, Ferruccio, and Basolo, Fulvio
- Subjects
THYROID cancer ,CANCER patients ,IMMUNOHISTOCHEMISTRY ,THYROID gland tumors ,SENSITIVITY & specificity (Statistics) ,FOLLICULAR dendritic cells ,THYROTROPIN receptors - Abstract
Patients with advanced thyroid cancer harboring NTRK rearrangements can be treated with highly effective selective inhibitors. Immunohistochemistry (IHC) analysis, to detect Trk protein expression, represents an appealing screening strategy for NTRK rearrangements, but its efficacy has been poorly explored in thyroid cancer. The aim of this study is to investigate the diagnostic utility of Trk IHC in the identification of NTRK rearrangements. A series of 26 follicular-derived thyroid tumors, positive for NTRK rearrangements, and 28 NTRK fusion-negative controls were retrospectively analyzed by IHC using the pan-Trk monoclonal antibody (clone EPR17341) on the Ventana system. Area under the curve (AUC), sensitivity and specificity were calculated by ROC analysis. Trk expression was detected in 25 samples, including 22 out of the 26 NTRK-rearranged (84.6%) and three out of 28 NTRK-negative samples (10.7%). Four out of twenty-six NTRK-rearranged thyroid tumors were negative for Trk expression (15.4%), all carrying the ETV6/NTRK3 fusion. The AUC, sensitivity and specificity were 0.87, 0.85 and 0.89, respectively. A screening based on IHC analysis showed limited sensitivity and specificity in the identification of NTRK-rearranged tumors. Since falsely negative results could preclude the administration of effective targeted drugs, alternative detection strategies should be considered for thyroid cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Predictive Biomarkers in Thyroid Cancer.
- Author
-
Macerola, Elisabetta, Poma, Anello Marcello, Vignali, Paola, Proietti, Agnese, Ugolini, Clara, Torregrossa, Liborio, Basolo, Alessio, Elisei, Rossella, Santini, Ferruccio, and Basolo, Fulvio
- Subjects
THYROID cancer ,SINGLE nucleotide polymorphisms ,TUMOR markers ,THYROTROPIN ,MOLECULAR pathology ,SORAFENIB ,TUMOR growth - Abstract
In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced thyroid cancer included multi-tyrosine kinase inhibitors, mainly targeting the MAPK pathway and the angiogenic signaling. The administration of these drugs does not necessarily require a molecular characterization of tumors to assess the presence of predictive alterations. However, the availability of new selective targeted drugs for thyroid cancer patients is changing the diagnostic strategies for the molecular characterization of these tumors. The search for targetable alterations can be performed directly on tumor tissue by using a variety of methodologies, depending also on the number and type of alterations to test (i.e. single nucleotide variation or gene rearrangement). Herein, a comprehensive review of the currently available targeted treatments for thyroid cancer, related predictive markers and testing methodologies is provided. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Nutrition in Advanced Thyroid Cancer Patients.
- Author
-
Agate, Laura, Minaldi, Elisa, Basolo, Alessio, Angeli, Valentina, Jaccheri, Roberta, Santini, Ferruccio, and Elisei, Rossella
- Abstract
In the last decade, multikinase inhibitors (MKIs) have changed the paradigm of treatment of advanced and progressive thyroid cancer. Compared with the traditional treatment with chemotherapy and radiotherapy, these new drugs have shown a good efficacy in controlling the neoplastic disease, and also a different toxicity profile compared to traditional chemotherapy, milder but still present and involving mainly the nutritional profile. Weight loss, nausea, anorexia, stomatitis, diarrhea may be associated with malnutrition and cancer-related cachexia. The latter is characteristic of the advanced cancer stage and may be present before starting MKIs, or may develop afterwards. Adverse events with nutritional impact may cause a significant impairment of quality of life, often requiring dose reduction and sometimes drug discontinuation, but with a lower efficacy on the neoplastic disease. The aim of this paper was to discuss the role of nutritional therapy in advanced thyroid cancer and the importance of prevention, early recognition and careful management of malnutrition and cachexia during systemic therapy with MKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma.
- Author
-
Poma, Anello Marcello, Macerola, Elisabetta, Proietti, Agnese, Vignali, Paola, Sparavelli, Rebecca, Torregrossa, Liborio, Matrone, Antonio, Basolo, Alessio, Elisei, Rossella, Santini, Ferruccio, and Ugolini, Clara
- Subjects
PAPILLARY carcinoma ,THYROID cancer ,LYMPHADENECTOMY ,TREATMENT effectiveness ,LYMPHATIC metastasis ,DISEASE progression - Abstract
Papillary thyroid carcinoma (PTC) with hobnail areas above 30% is classified as hobnail variant (HVPTC). Although it is widely accepted that HVPTC has a worse outcome than classical PTC, it is unclear whether PTC with hobnail features below 30% is as aggressive as HVPTC. We gathered the largest mono-institutional series of PTC with hobnail areas and HVPTC to evaluate differences in terms of pathological features of aggressiveness, molecular profile, and treatment outcome. A total of 99 PTC with hobnail features above 5% were retrospectively selected; 34 of them met the criteria for HVPTC (0.4% of all PTC diagnosed at our institution). All tumors showed high rates of extra-thyroidal extension (40.4%), lymph node metastasis (68.1% of patients with lymphadenectomy), and vascular emboli (49.5%), with no differences according to the 30% cutoff. On the other hand, distant metastases were present in HVPTC only (9.4%). Also, advanced age, advanced disease stage, and TERT promoter mutation were associated with HVPTC. More than half of the patients with follow-up had structural or biochemical persistence after 1 year from surgery. Structural persistence was significantly more common in patients with HVPTC (37.5% vs. 8.7%), while no differences were observed considering structural and biochemical persistence together. The presence of hobnail features identifies locally aggressive tumors, and, consequently, it should be always acknowledged in the pathological report. However, tumors with more than 30% hobnail areas frequently present TERT promoter mutations, advanced disease stage, and structural persistence after radioiodine ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
- Author
-
Yubing Tao, Fei Wang, Xiaopei Shen, Guangwu Zhu, Rengyun Liu, Viola, David, Elisei, Rossella, Puxeddu, Efisio, Fugazzola, Laura, Colombo, Carla, Jarzab, Barbara, Czarniecka, Agnieszka, Lam, Alfred K., Mian, Caterina, Vianello, Federica, Yip, Linwah, Riesco-Eizaguirre, Garcilaso, Santisteban, Pilar, O'Neill, Christine J., and Sywak, Mark S.
- Subjects
BRAF genes ,LYMPH node diseases ,THYROID cancer ,RESEARCH ,GENETIC mutation ,THYROID gland tumors ,RESEARCH methodology ,CANCER relapse ,METASTASIS ,RETROSPECTIVE studies ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,TRANSFERASES ,RESEARCH funding ,LONGITUDINAL method - Abstract
Context: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined.Objective: To study whether BRAF V600E affected LNM-associated mortality in PTC.Design, Setting, and Participants: We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 [interquartile range (IQR) 35-58] years and median follow-up time of 58 (IQR 26-107) months.Results: Overall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAF V600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAF V600E patients; mortality rates were 2/659 (0.3%) vs 4/321 (1.2%) in non-LNM vs LNM patients (P = 0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAF V600E CPTC, morality rates were 7/515 (1.4%) vs 28/363 (7.7%) in non-LNM vs LNM patients (P < 0.001), corresponding to an HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAF V600E vs absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism.Conclusions: LNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
23. Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer.
- Author
-
Giani, Carlotta, Torregrossa, Liborio, Ramone, Teresa, Romei, Cristina, Matrone, Antonio, Molinaro, Eleonora, Agate, Laura, Materazzi, Gabriele, Piaggi, Paolo, Ugolini, Clara, Basolo, Fulvio, Ciampi, Raffaele, and Elisei, Rossella
- Subjects
PROGNOSIS ,THYROID cancer ,TUMORS - Abstract
Context: Tumor capsule integrity is becoming a relevant issue to predict the biological behavior of human tumors, including thyroid cancer. Objective: This work aims to verify whether a whole tumor capsule in the classical variant of papillary thyroid carcinoma (CVPTC) could have as a predictive role of a good outcome as for follicular variant (FVPTC). Methods: FVPTC (n = 600) and CVPTC (n = 554) cases were analyzed. We distinguished between encapsulated-FVPTC (E-FVPTC) and encapsulated-CVPTC (E-CVPTC) and, thereafter, invasive (Ei-FVPTC and Ei-CVPTC) and noninvasive (En-FVPTC and En-CVPTC) tumors, according to the invasion or integrity of the tumor capsule, respectively. Cases without a tumor capsule were indicated as invasive-FVPTC (I-FVPTC) and invasive-CVPTC (I-CVPTC). The subgroup of each variant was evaluated for BRAF mutations. Results: E-FVPTC was more frequent than E-CVPTC (P < .001). No differences were found between En-FVPTC and En-CVPTC or between Ei-FVPTC and Ei-CVPTC. After 18 years of follow-up, a greater number of not-cured cases were observed in Ei-CVPTC with respect to Ei-FVPTC, but not in En-CVPTC to En-FVPTC. Multivariate clustering analysis showed that En-FVPTC, En-CVPTC, and Ei-FVPTC have similar features but different from I-FVPTC and I-CVPTC and, to a lesser extent, from Ei-CVPTC. A total of 177 of 614 (28.8%) cases were BRAFV600E mutated, and 10 of 614 (1.6%) carried BRAF-rare alterations. A significantly higher rate of En-CVPTC (22/49, 44.9%) than En-FVPTC (15/195, 7.7%) (P < .0001) were BRAFV600E mutated. Conclusion: En-CVPTC is less prevalent than En-FVPTC. However, it has good clinical/pathological behavior comparable to En-FVPTC. This finding confirms the good prognostic role of a whole tumor capsule in CVPTC as well. New nomenclature for En-CVPTC, similar to that introduced for En-FVPTC (ie, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; NIFTP) could be envisaged. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.
- Author
-
Poma, Anello Marcello, Viola, David, Macerola, Elisabetta, Proietti, Agnese, Molinaro, Eleonora, De Vietro, Dario, Elisei, Rossella, Materazzi, Gabriele, Miccoli, Paolo, Basolo, Fulvio, and Ugolini, Clara
- Subjects
THYROID cancer ,HEALTH management - Abstract
Context: Recent diagnostic criteria updates of the tall cell variant of papillary thyroid carcinoma (TCPTC) by the World Health Organization (WHO) have determined the inclusion of tumors with 30% to 49% of tall cells. However, the impact of tall cell percentage on papillary thyroid carcinoma (PTC) patients' prognosis is still debated. Objective: We aimed to evaluate whether tall cell percentage affects patient outcome in the absence of aggressive features. Methods: Rates of aggressive features, recurrence-free survival (RFS), and distant RFS (5-year median follow-up) were compared among tumors with less than 30%, 30% to 49% and at least 50% tall cells. We also evaluated the impact of the new tall cell cutoff on patient management. Results: Overall, 3092 tumors (15.7% of all PTCs) were collected: A total of 792 PTCs had less than 30%, 503 had 30% to 49%, and 1797 had 50% or more tall cell areas. With the new WHO definition, the number of TCPTCs increased by 28%. There were no differences in recurrence rates according to tall cell percentage. The coexistence of BRAF and TERT promoter mutations predicted a worse RFS. Considering the new definition of TCPTC, the level of risk according to the American Thyroid Association increased from low to intermediate in 4.2% of cases. However, the recurrence rate within this subgroup was comparable to low risk. Conclusion: TCPTC and PTC with tall cell areas can be considered as a unique group with similar recurrence risk. However, whenever aggressive features are absent, tumors have a low risk of recurrence independently of tall cell percentage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
- Author
-
Valerio, Laura, Guidoccio, Federica, Giani, Carlotta, Tardelli, Elisa, Puccini, Giulia, Puleo, Luciana, Minaldi, Elisa, Boni, Giuseppe, Elisei, Rossella, and Volterrani, Duccio
- Subjects
THYROID cancer ,CANCER patients ,PROTEIN-tyrosine kinase inhibitors ,THERAPEUTIC use of antineoplastic agents ,ADENOCARCINOMA ,QUINOLINE ,RESEARCH ,UREA ,THYROID gland tumors ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,IODINE radioisotopes ,TREATMENT effectiveness ,DIAGNOSTIC imaging ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,RESEARCH funding ,DEOXY sugars ,COMPUTED tomography - Abstract
Context: 18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography ([18F]-FDG-PET/CT)-positive metastatic lesions in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) have a poor prognosis and lenvatinib represents the best therapy.Objective: We investigated the role of [18F]-FDG-PET/CT in the evaluation of metabolic response and prediction of the outcome of RAI-R DTC patients treated with lenvatinib.Methods: Patients (n = 33) with progressive metastatic RAI-R DTC who were treated with lenvatinib were investigated at baseline and during follow-up with biochemical (thyroglobulin and thyroglobulin antibodies), morphological (whole-body CT scan) and metabolic ([18F]-FDG-PET/CT) evaluation.Results: Nineteen (57.6%) patients showed the greatest metabolic response at the first [18F]-FDG-PET/CT scan, performed after 4 weeks of lenvatinib, while 5/33 (15.1%) patients had this response later. Moreover, 66.7% of patients had both a metabolic response at the first [18F]-FDG-PET/CT scan and a morphological response at the first CT scan. We observed a correlation between the metabolic response at [18F]-FDG-PET/CT scan performed after 4 weeks of treatment and the biochemical response at the same time in 60.6% of patients. The median overall survival (OS) was significantly longer in patients with either a metabolic response at last [18F]-FDG-PET/CT (40.00 vs 8.98 months) or a morphological response at last CT scan (37.22 vs 9.53 months) than in those without response. Moreover, the OS was longer in patients with a metabolic response at [18F]-FDG-PET/CT performed after 4 weeks of treatment (36.53 vs 11.28 months).Conclusions: Our data show that [18F]-FDG-PET/CT can early predict the response to lenvatinib and correlates with the OS of RAI-R DTC patients treated with this drug. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
26. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
- Author
-
Taylor, Matthew H., Takahashi, Shunji, Capdevila, Jaume, Tahara, Makoto, Leboulleux, Sophie, Kiyota, Naomi, Dutcus, Corina E., Xie, Ran, Robinson, Bruce, Sherman, Steven, Habra, Mouhammed Amir, Elisei, Rossella, and Wirth, Lori J.
- Subjects
NEUTROPHIL lymphocyte ratio ,THYROID cancer ,OVERALL survival ,PROGNOSIS ,PROGRESSION-free survival - Abstract
Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor approved for the treatment of RR-DTC. This study aims to assess Eastern Cooperative Oncology Group performance status (ECOG PS) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for patients with RR-DTC treated with lenvatinib. Methods: In this retrospective analysis of the Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT), patients randomly assigned to receive lenvatinib were classified according to baseline ECOG PS (0 or 1) or baseline NLR (≤3 or >3). The effects of baseline ECOG PS and NLR on progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were evaluated. In addition, the effects of baseline ECOG PS on the change in diameter of target lesions and correlations between baseline NLR and the sums of the diameters of target lesions were calculated. Results: Among patients who received lenvatinib, patients with a baseline ECOG PS of 0 had statistically improved PFS (hazard ratio [HR] 0.52; 95% confidence interval [CI 0.35–0.77]; p = 0.001), OS (HR 0.42 [CI 0.26–0.69]; p = 0.0004), and ORR (odds ratio [OR] 3.51 [CI 2.02–6.10]; p < 0.0001) compared with patients with a baseline ECOG PS of 1. Patients who received lenvatinib with a baseline NLR ≤3 also had improved PFS (HR 0.43 [CI 0.29–0.65]; p < 0.0001) and OS (HR 0.48 [CI 0.29–0.78]; p = 0.0029) versus patients with a baseline NLR >3. Moreover, patients with a baseline NLR ≤3 had a trend toward increased ORR (OR 1.57 [CI 0.94–2.64]; p = 0.08) compared with patients with a baseline NLR >3. Treatment-emergent adverse events were generally similar among patients who received lenvatinib, irrespective of patients' ECOG PS at baseline. Conclusion: Lower ECOG PS and NLR may provide prognostic value for improved efficacy in patients with RR-DTC. ClinicalTrials.gov no. NCT01321554. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System.
- Author
-
Corrado, Alda, Aceto, Romina, Silvestri, Roberto, Dell'Anno, Irene, Ricci, Benedetta, Miglietta, Simona, Romei, Cristina, Giovannoni, Roberto, Poliseno, Laura, Evangelista, Monica, Vitiello, Marianna, Cipollini, Monica, Garritano, Sonia, Giusti, Laura, Zallocco, Lorenzo, Elisei, Rossella, Landi, Stefano, and Gemignani, Federica
- Subjects
GALECTINS ,CRISPRS ,THYROID cancer ,SINGLE nucleotide polymorphisms ,GENE expression ,GENE silencing - Abstract
Background: Galectin-3 (LGALS3) is an important glycoprotein involved in the malignant transformation of thyrocytes acting in the extracellular matrix, cytoplasm, and nucleus where it regulates TTF-1 and TCF4 transcription factors. Within LGALS3 gene, a common single-nucleotide polymorphism (SNP) (c.191C>A, p.Pro64His; rs4644) encoding for the variant Proline to Histidine at codon 64 has been extensively studied. However, data on rs4644 in the context of thyroid cancer are lacking. Thus, the aim of the present work was to evaluate the role of the rs4644 SNP as risk factor for differentiated thyroid cancer (DTC) and to determine the effect on the transcriptome in thyrocytes. Methods: A case/control association study in 1223 controls and 1142 unrelated consecutive DTC patients was carried out to evaluate the association between rs4644-P64H and the risk of DTC. We used the nonmalignant cell line Nthy-Ori (rs4644-C/A) and the CRISPR/Cas9 technique to generate isogenic cells carrying either the rs4644-A/A or rs4644-C/C homozygosis. Then, the transcriptome of the derivative and unmodified parental cells was analyzed by RNA-seq. Genes differentially expressed were validated by quantitative reverse transcription PCR and further tested in the parental Nthy-Ori cells after LGALS3 gene silencing, to investigate whether the expression of target genes was dependent on galectin-3 levels. Results: rs4644 AA genotype was associated with a reduced risk of DTC (compared with CC, OR
adj = 0.66; 95% confidence interval = 0.46–0.93; Pass = 0.02). We found that rs4644 affects galectin-3 as a transcriptional coregulator. Among 34 genes affected by rs4644, HES1, HSPA6, SPC24, and NHS were of particular interest since their expression was rs4644-dependent (CC>AA for the first and AA>CC for the others), also in 574 thyroid tissues of Genotype-Tissue Expression (GTEx) biobank. Moreover, the expression of these genes was regulated by LGALS3-silencing. Using the proximity ligation assay in Nthy-Ori cells, we found that the TTF-1 interaction was genotype dependent. Conclusions: Our data show that in thyroid, rs4644 is a trans-expression quantitative trait locus that can modify the transcriptional expression of downstream genes, through the modulation of TTF-1. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
28. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
- Author
-
Giani, Carlotta, Valerio, Laura, Bongiovanni, Alberto, Durante, Cosimo, Grani, Giorgio, Ibrahim, Toni, Mariotti, Stefano, Massa, Michela, Pani, Fabiana, Pellegriti, Gabriella, Porcelli, Tommaso, Salvatore, Domenico, Tavarelli, Martina, Torlontano, Massimo, Locati, Laura, Molinaro, Eleonora, and Elisei, Rossella
- Subjects
SYMPTOMS ,THYROID cancer ,CANCER treatment ,QUALITY of life ,APPETITE loss ,WEIGHT loss - Abstract
Background: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. However, there are a lot of drug-related adverse events (AEs) that can affect the quality of life (QoL) of patients. The aims of this study were (a) to evaluate, and compared with other series, the safety of lenvatinib used in RR-DTC patients enrolled in an Italian expanded access program (EAP), and (b) to evaluate their QoL during treatment with lenvatinib. Methods: To evaluate the safety, we recorded and graded all AEs during the 6 months of lenvatinib treatment in 39 RR-DTC patients. We compared the safety profile of lenvatinib observed in our patients with that reported in the study of (E7080) levatinib in differentiated cancer of the thyroid (SELECT) and tumeurs thyroidiennes refractaires (TUTHYREF) network studies. Moreover, we evaluated the QoL in our series by using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 and the pain visual analogue scale (VAS). Results: The most frequent AEs among our 39 RR-DTC patients were hypertension (80.5%), fatigue (58.3%), diarrhea (36.1%), stomatitis (33.3%), hand/foot syndrome (33.3%), and weight loss (30.5%). The most prevalent grade 3/4 AE was hypertension (25%). When compared with previous studies (i.e., SELECT and TUTHYREF), a significantly lower percentage of our patients experienced diarrhea, nausea, proteinuria, and weight loss. No statistically significant differences in the QoL of our patients evaluated before, during, and at the end of follow-up (6 months after starting the therapy) were found. However, a slight improvement of the general health and emotional and cognitive status associated with a slightly worsening of physical role and social functioning was observed during these 6 months. Pain, dyspnea, insomnia, and constipation moved toward better values, while fatigue, nausea and vomiting, appetite loss, and diarrhea worsened. By comparing the pain VAS, an overall reduction of the level of pain was found. Conclusions: The safety profile of the drug was similar to that already reported with some differences in the prevalence and severity of the AEs. Regarding the QoL, the EAP showed a trend of improvement of the global health status and a reduction of symptoms correlated to the disease. The clinical impact of fatigue, anorexia/weight loss and stomatitis, mainly due to the drug itself, continues to represent the major issue in the management of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
- Author
-
Cappagli, Virginia, Caldarella, Adele, Manneschi, Gianfranco, Piaggi, Paolo, Bottici, Valeria, Agate, Laura, Molinaro, Eleonora, Bianchi, Francesca, and Elisei, Rossella
- Subjects
CANCER patients ,THYROID cancer ,URINARY organs - Abstract
The long‐term survival of differentiated thyroid cancer (DTC) patients and the need to perform several treatments with radioiodine (131‐I) lead to the question if the lifetime risk of developing a nonthyroidal second primary cancer (NTSPC) is increased in these patients. In our study, we assessed the prevalence of NTSPCs in thyroid cancer population and evaluated the possible causative role of 131‐I treatment. We analyzed 1096 consecutive patients followed at our institution from 1964 to 1998. A total of 101 NTSPCs were observed in 92/1096 patients (8.4%) among which 17/101 (16.8%) diagnosed before DTC and 84/101 (83.2%) diagnosed after. The most frequent tumor sites observed were breast and bladder/urinary tract in the post‐DTC group and breast and hematological system in the pre‐DTC group. Regarding 131‐I treatment, we did not observe any significant differences regarding either the number of treatments or the cumulative activity. The only significant parameter associated with an increased incidence of NTSPC was follow‐up (P =.02): a longer follow‐up period was associated with a higher number of NTSPCs. The mean latency between 131‐I and NTSPC was 10.52 ± 7.69 years. Comparing with the general Italian population, independent of radioiodine treatment, the standard incidence ratio in our cohort was similar to that of the general population (SIR 1.07) and this result was confirmed by analyzing only the treated group. In conclusion, these results show that the risk of NTSPCs in the DTC patients' population is similar to that in the general population and 131‐I treatment was not associated with an increased risk. What's new? Whether radioiodine treatment for differentiated thyroid cancer (DTC) increases risk of second non‐thyroidal primary cancer (NTSPC) is unclear. In this retrospective study, second primary cancer incidence was investigated in more than 1000 DTC patients treated with radioiodine in Italy from 1964 to 1998. Analyses show that 8.4% of patients had NTSPCs, though about one‐sixth of these were diagnosed before DTC. Despite the frequency of NTSPC, independent of radioiodine, overall NTSPC risk in patients was not significantly different from risk in the general Italian population. Moreover, radioiodine treatment was not correlated with increased cumulative risk of second primary cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma.
- Author
-
Gemignani, Federica, Romei, Cristina, Ciampi, Raffaele, Corrado, Alda, Melaiu, Ombretta, Figlioli, Gisella, Bonotti, Alessandra, Foddis, Rudy, Cristaudo, Alfonso, Pellegrini, Giovanni, Vivaldi, Agnese, Cipollini, Monica, Landi, Stefano, and Elisei, Rossella
- Subjects
MEDULLARY thyroid carcinoma ,SINGLE nucleotide polymorphisms ,THYROID cancer ,MESSENGER RNA ,GENE frequency ,THYROID gland - Abstract
Background: Sporadic medullary thyroid carcinoma (sMTC) is an uncommon neoplasia arising from the calcitonin-producing parafollicular cells of the thyroid. Previous studies evaluated whether single nucleotide polymorphisms (SNPs) within RET (a pivotal proto-oncogene for this disease) are associated with the risk for developing sMTC, but the results are inconclusive. Methods: In this work, we evaluated the association of RET-SNPs c.74-126G>T (rs2565206), p.Gly691Ser (rs1799939, G>A), p.Leu769 = (rs1800861, G>T), p.Ser836 = (rs1800862, C>T), and p.Ser904 = (rs1800863, C>G) (listed in the order of their chromosomal location) with sMTC. This is one of the largest case–control association studies carried out on sMTC, including 585 sMTC cases (negative for germline mutations within RET), 1529 patients affected by sporadic nonmedullary thyroid carcinoma (sNMTC), and 989 healthy controls, from central and southern Italy and collected in the period 2000–2017. Results: sNMTC patients showed similar genotype and allele frequencies compared with healthy controls. On the other hand, among sMTC patients, the T-allele of p.Leu769 = was less frequent (OR = 0.70 [CI 0.58–0.84], p = 1.9 × 10
−4 ) and rare homozygotes TT showed an OR = 0.32 ([CI 0.17–0.60], p = 2.3 × 10−4 ). Moreover, a statistically significant excess of the haplotype 2 (characterized by the alleles T-G-G-C-C of the listed SNPs) was observed (p = 3.9 × 10−3 ). The SNPs were not associated with the expression of RET mRNA, that is, they did not exert an effect in cis as quantitative trait locus (cis-eQTL). However, a strong eQTL association was found for p.Leu769 = and the neighboring gene CSGALNACT2 (p = 9.3 × 10−50 ; effect-size = −0.65), whose function in cancer is unknown. Conclusions: This study shows that specific RET haplotypes, in particular haplotype 2 and the T-allele of p.Leu769 = , are associated with a reduced risk of sMTC in Italians. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
31. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
- Author
-
Reiners, Christoph, Schneider, Rita, Platonova, Tamara, Fridman, Mikhail, Malzahn, Uwe, Mäder, Uwe, Vrachimis, Alexis, Bogdanova, Tatiana, Krajewska, Jolanta, Elisei, Rossella, Vaisman, Fernanda, Mihailovic, Jasna, Costa, Gracinda, and Drozd, Valentina
- Subjects
BREAST cancer ,THYROID cancer ,IODINE isotopes ,LITERATURE reviews ,CANCER treatment ,RADIATION carcinogenesis - Abstract
Published studies on the risk of radiation-induced second primary malignancy (SPM) after radioiodine treatment (RAI) of differentiated thyroid cancer (DTC) refer mainly to patients treated as middle-aged or older adults and are not easily generalizable to those treated at a younger age. Here we review available literature on the risk of breast cancer as an SPM after RAI of DTC with a focus on females undergoing such treatment in childhood, adolescence, or young adulthood. Additionally, we report the results of a preliminary international survey of patient registries from academic tertiary referral centers specializing in pediatric DTC. The survey sought to evaluate the availability of sufficient patient data for a potential international multicenter observational case–control study of females with DTC given RAI at an early age. Our literature review identified a bi-directional association of DTC and breast cancer. The general breast cancer risk in adult DTC survivors is low, ~2%, slightly higher in females than in males, but presumably lower, not higher, in those diagnosed as children or adolescents than in those diagnosed at older ages. RAI presumably does not substantially influence breast cancer risk after DTC. However, data from patients given RAI at young ages are sparse and insufficient to make definitive conclusions regarding age dependence of the risk of breast cancer as a SPM after RAI of DTC. The preliminary analysis of data from 10 thyroid cancer registries worldwide, including altogether 6,449 patients given RAI for DTC and 1,116 controls, i.e., patients not given RAI, did not show a significant increase of breast cancer incidence after RAI. However, the numbers of cases and controls were insufficient to draw statistically reliable conclusions, and the proportion of those receiving RAI at the earliest ages was too low.In conclusion, a potential international multicenter study of female patients undergoing RAI of DTC as children, adolescents, or young adults, with a sufficient sample size, is feasible. However, breast cancer screening of a larger cohort of DTC patients is not unproblematic for ethical reasons, due to the likely, at most slightly, increased risk of breast cancer post-RAI and the expected ~10% false-positivity rate which potentially produced substantial "misdiagnosis." [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy.
- Author
-
Matrone, Antonio, Torregrossa, Liborio, Sensi, Elisa, Cappellani, Daniele, Baronti, Walter, Ciampi, Raffaele, Molinaro, Eleonora, Ugolini, Clara, Aghababyan, Aleksandr, De Napoli, Luigi, Latrofa, Francesco, Materazzi, Gabriele, Basolo, Fulvio, Vitti, Paolo, and Elisei, Rossella
- Subjects
ANAPLASTIC thyroid cancer ,LUNG cancer ,TUMOR markers ,THYROID gland - Abstract
The diagnosis of the primary origin of metastases to the thyroid gland is not easy, in particular in case of concomitant lung adenocarcinoma which shares several immunophenotypical features. Although rare, these tumors should be completely characterized in order to set up specific therapies. This is the case of a 64-years-old woman referred to our institution for a very advanced neoplastic disease diagnosed both as poorly differentiated/anaplastic thyroid cancer (PDTC/ATC) for the huge involvement of the neck and concomitant lung adenocarcinoma (LA). Neither the clinical features and the imaging evaluation nor the tumor markers allowed a well-defined diagnosis. Moreover, the histologic features of the thyroid and lung biopsies confirmed the synchronous occurrence of two different tumors. The molecular analysis showed a c.34G>T (p.G12C) mutation in the codon 12 of K-RAS gene, in both tissues. Since, this mutation is highly prevalent in LA and virtually absent in PDTC/ATC the lung origin of the malignancy was assumed, and the patient was addressed to the correct therapeutic strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer.
- Author
-
Molinaro, Eleonora, Viola, David, Viola, Nicola, Falcetta, Pierpaolo, Orsolini, Francesca, Torregrossa, Liborio, Vagli, Paola, Ribechini, Alessandro, Materazzi, Gabriele, Vitti, Paolo, and Elisei, Rossella
- Subjects
THYROID cancer ,THYROIDECTOMY ,NASOENTERAL tubes ,IODINE isotopes ,ESOPHAGEAL perforation ,PROTEIN-tyrosine kinases ,SALINE solutions - Abstract
Background. The tyrosine kinase inhibitors (TKIs) are indicated for the treatment of locally advanced or metastatic progressive thyroid carcinoma (CDT), refractory to radioactive iodine. The following report describes the efficacy of lenvatinib administered through a nose-gastric tube (SNG) in a patient affected with a poorly differentiated thyroid carcinoma (PDTC) which determined a stenosis of the esophagus. Material and Methods. A patient was followed up for papillary thyroid carcinoma follicular variant (T3NxMx), subjected to total thyroidectomy and treated with iodine-131 radio metabolic therapy. Two years after surgery, following the onset of dysphonia and dysphagia, patient was submitted to a computed tomography (CT) scan of the neck that showed the presence of a lesion of 6 × 2.5 × 3.5 cm, which determined trachea deviation and cervical esophagus compression. The biopsy indicated the presence of PDTC, triggering tracheal lumen reduction and sub-stenosis of the cervical esophagus for an ab-extrinsic compression. A nose-gastric tube (SNG) was placed and lenvatinib was started at a dose of 20 mg/day, administered via this probe after opening the capsules and diluting the drug in 10 ml of saline solution. Results. One month later, CT showed a significant cervical lesion reduction. Bronchoscopy confirmed tracheal infiltration, but the residual caliber was improved from 50% to 75%. At the esophagogastroduodenoscopy (EGDS), the sub stenosis of the cervical esophagus was no longer appreciated; however, a double perforation of the esophagus was found, without fistula. Conclusion. Lenvatinib therapy is effective also when administered via SNG. Our result is of particular relevance in the management of thyroid cancer patients, especially in the presence of subjects unable to swallow. Further studies are needed to validate the administration of lenvatinib by SNG, in order to extend the indications to this alternative administration way, beside the oral one. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
- Author
-
Hu, Mimi I., Elisei, Rossella, Dedecjus, Marek, Popovtzer, Aron, Druce, Maralyn, Kapiteijn, Ellen, Pacini, Furio, Locati, Laura, Krajewska, Jolanta, Weiss, Richard, and Gagel, Robert F.
- Subjects
- *
THYROID cancer , *MEDULLARY thyroid carcinoma , *PROTEIN-tyrosine kinases - Abstract
Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced symptomatic or progressive medullary thyroid cancer (MTC). The current study (NCT01496313) evaluated the benefit-risk of two starting doses of vandetanib in patients with symptomatic or progressive MTC. Patients were randomized 1:1 to receive vandetanib 150 or 300 mg daily and followed for a maximum of 14 months (Part A), with the option to then enter an open-label phase (Part B) inve stigating vandetanib 100, 150, 200 and 300 mg daily doses. Efficacy was assessed in Pa rt A, and safety and tolerability during Parts A and B up to 2 years post randomizat ion. Eighty-one patients were randomized in Part A and 61 patients entered Part B, of wh om 37 (60.7%) received 2 years of treatment. Overall, 25% of patients experienced an objective response (OR) at 14 months (OR rate, 0.29 (95% CI, 0.176-0.445) for 300 mg, and 0.20 (95% CI, 0.105-0.348) for 150 mg; one-sided P value approximately 0.43). The most common adverse events (AEs) included diarrhea, hypocalcemia, asthenia, QTc prolongation, hypokalemia and keratopathy, all at generally higher incidence with 300 vs 150 mg (Part A). Part B safety and tolerability was consistent with Part A. OR was observed wi th both vandetanib doses; the 300 mg dose showed a more favorable trend vs 150 mg as init ial dose. Thus, for most patients, 300 mg vandetanib is the most appropriate starting dose; dose reductions to manage AEs and lower initial doses for patients with particular comorbidities can be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology.
- Author
-
Rago, Teresa, Scutari, Maria, Loiacono, Valeria, Tonacchera, Massimo, Scuotri, Giuditta, Romani, Rossana, Proietti, Agnese, Piaggi, Paolo, Elisei, Rossella, Basolo, Fulvio, Latrofa, Francesco, and Vitti, Paolo
- Subjects
CYTOLOGY ,HISTOLOGY ,THYROID cancer ,CARCINOMA ,DISEASE remission - Abstract
Background: The outcomes of patients with thyroid cancer proven by histology in patients in whom cytology was Thy 3 (indeterminate; Thy 3 patients in this study) based on the Italian consensus classification compared with those in whom cytology was Thy 4 (suspicious for malignancy) or Thy 5 (indicative for malignancy) (Thy 4–5 patients here) remains unclear. Objective: To analyze the outcome of 371 Thy 3 patients versus 269 Thy 4–5 patients homogeneously treated with total thyroidectomy and
131 I activity. Results: T1 stage was observed in 46.0% of Thy 3 and in 38.8% of Thy 4–5 patients (p = 0.02), N0 in 95.9% of Thy 3 and in 75.5% of Thy 4–5 patients (p < 0.0001). 35/261 (9.6%) Thy 3 and 85/269 (31.5%) Thy 4–5 patients required >30 mCi of131 I (p < 0.0001). 359/371 (96.8%) Thy 3 and 232/269 (86.2%) Thy 4–5 patients were free of disease at the end of follow-up (p < 0.001). The time required to obtain 50% of patients in remission was 2 years in Thy 3 and 4 years in Thy 4–5 patients (p < 0.001). The most common histological type was the follicular variant of papillary thyroid carcinoma (FV-PTC) in Thy 3 patients (239/371, 64.4%) and the classic variant in Thy 4–5 patients (185/269; 68.8%). The FV-PTC had better prognostic features compared with the other PTC variants: T1 stage was observed in 133/277 (48.0%) FV-PTC patients and in 146/363 (40.0%) patients with the other variants (p < 0.001), N0 was present in 265/277 (96.0%) FV-PTC and in 290/363 (79.8%) patients with the other variants (p < 0.001). Overall, 267/277 FV-PTC patients (96.4%) and 324/363 patients (89.0%) with the other variants were free of disease (p < 0.0008) at the end of follow-up, and the time required to obtain 50% of patients in remission was 2 years in FV-PTC and 4.0 years in the other variants (p < 0.001). Conclusion: Patients with Thy 3 cytology have better outcomes of thyroid cancer compared with patients with Thy 4 or Thy 5 cytology, and indeterminate cytology is commonly associated with the less aggressive FV-PTC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
36. Incidence of Anti-Thyroid Autoantibodies in Thyroid Cancer Patients
- Author
-
Pacini, Furio, Mariotti, Stefano, Formica, Nunzio, Elisei, Rossella, Anelli, Stefano, Capotorti, Enrico, Baschieri, Lidio, Pinchera, Aldo, Pinchera, A., editor, Ingbar, S. H., editor, McKenzie, J. M., editor, and Fenzi, G. F., editor
- Published
- 1987
- Full Text
- View/download PDF
37. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.
- Author
-
Condello, Vincenzo, Macerola, Elisabetta, Ugolini, Clara, De Napoli, Luigi, Romei, Cristina, Materazzi, Gabriele, Elisei, Rossella, and Basolo, Fulvio
- Subjects
CIRCULATING tumor DNA ,CANCER genetics ,HEAD & neck cancer patients ,HEAD & neck cancer treatment ,CANCER treatment - Abstract
Abstract: Background: Circulating cell‐free tumor DNA (ctDNA) in plasma is a promising noninvasive instrument for cancer monitoring. Detection of BRAF
V600E on ctDNA of patients with papillary thyroid carcinoma (PTC) may represent an indicator of tumor aggressiveness and progression. Methods: Eighty‐three plasma samples were collected from 70 patients with thyroid nodules undergoing surgery and from 13 patients with PTC causing distant metastases. A total of 59 PTCs from both groups were evaluated for BRAF mutation on tumor tissue and on ctDNA from plasma samples by real‐time polymerase chain reaction (PCR) and digital PCR. Results: Of 59 PTCs, 22 were BRAFV600E mutated (37.3%). The corresponding ctDNA was negative by using both techniques. Conclusion: Although highly sensitive techniques were used, in our study, circulating BRAFV600E alleles were never detected in the plasma of patients with PTC; therefore, our results raise the question about the clinical usefulness of BRAFV600E analysis on ctDNA of patients with PTC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
38. Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting.
- Author
-
Giannini, Riccardo, Ugolini, Clara, Poma, Anello Marcello, Urpì, Maria, Niccoli, Cristina, Elisei, Rossella, Chiarugi, Massimo, Vitti, Paolo, Miccoli, Paolo, and Basolo, Fulvio
- Subjects
THYROID cancer ,CANCER patients ,TUMORS ,GENE expression ,GENETIC mutation ,ADENOMA ,MOLECULAR pathology - Abstract
Background: The follicular variant (FV) of papillary thyroid cancer (PTC) is one of the most common variants of PTC. Clinically, non-infiltrative FVPTC is considered a low-risk variant of PTC, and the non-invasive encapsulated forms of FVPTC represent a group of thyroid tumors with a particularly good prognosis. Consequently, these neoplasms have been very recently reclassified as non-invasive follicular neoplasms with papillary-like nuclear features (NIFTP). From a molecular standpoint, NIFTP appears to be similar to follicular neoplasms. However, only limited data are currently available regarding their gene expression profile. Methods: The aim of this study was to identify specific molecular signatures of 26 NIFTPs compared to those of 19 follicular adenomas (FAs) and 18 infiltrative FVPTCs (IFVPTCs). A nanoString custom assay was used to perform mRNA expression analysis. All cases were also genotyped for BRAF, N-, H-, and K-RAS mutations. Samples were grouped on the basis of gene expression profiles by Pearson's correlation and non-negative matrix factorization clustering analysis. Finally, the uncorrelated shrunken centroid machine-learning algorithm was used to classify the samples. Results: The results revealed distinct expression profiles of FAs and IFVPTCs. NIFTP samples can exhibit different expression profiles, more similar to FAs (FA-like) or to IFVPTCs (IFVPTC-like), and these different expression profiles largely depend on the presence of different mutations ( RAS or BRAF). Conclusion: In conclusion, although further validation of the model is required by using a larger group of prospective cases, these data reinforce the hypothesis that IFVPTC-like NIFTPs might represent precursors of IFVPTC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Response to Letter to the Editor From Green and Gosmanov: "Tall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patients' Clinical Management".
- Author
-
Viola, David, Poma, Anello Marcello, Elisei, Rossella, and Basolo, Fulvio
- Subjects
THYROID cancer ,CLINICAL trials - Published
- 2022
- Full Text
- View/download PDF
40. Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis.
- Author
-
Molinaro, Eleonora, Elisei, Rossella, and Romei, Cristina
- Subjects
THYROID cancer diagnosis ,MOLECULAR oncology ,CYTOLOGY - Abstract
Introduction: The gold standard for the presurgical diagnosis of thyroid cancer is fine needle aspiration cytology. In about 30% of cases a final diagnosis is not obtained and surgical treatment is required for diagnostic/therapeutic purposes. To avoid unnecessary thyroidectomies, methods based on molecular markers analysis have been explored over the last 10 years. Areas covered: The present review introduces the limits of the cytological diagnosis of thyroid nodules and describes the molecular techniques for the presurgical diagnosis of these nodules focusing on the use of the Thyroseq-V2 (Rule in) and Afirma (Rule out) tests. Expert commentary: These two types of tests have been clinically applied and validated; however they are still confined to specialized laboratories, either academic or private, and not yet routinely used. The evidence of a positive cost-benefit analysis should encourage to set up molecular pathology laboratories to apply new molecular testing(s). In the meantime, clinical judgment, which must take into consideration several parameters including the age of the patient, the size and number of the nodule(s), the ultrasound pattern and the risk level for malignancy, should guide the decision to operate or to follow up the evolution of the nodule. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Inherited variants in genes somatically mutated in thyroid cancer.
- Author
-
Campo, Chiara, Köhler, Aleksandra, Figlioli, Gisella, Elisei, Rossella, Romei, Cristina, Cipollini, Monica, Bambi, Franco, Hemminki, Kari, Gemignani, Federica, Landi, Stefano, and Försti, Asta
- Subjects
SOMATIC mutation ,THYROID cancer ,TUMOR suppressor genes ,GERM cells ,SINGLE nucleotide polymorphisms - Abstract
Background: Tumour suppressor genes when mutated in the germline cause various cancers, but they can also be somatically mutated in sporadic tumours. We hypothesized that there may also be cancer-related germline variants in the genes commonly mutated in sporadic well-differentiated thyroid cancer (WDTC). Methods: We performed a two-stage case-control association study with a total of 2214 cases and 2108 healthy controls from an Italian population. By genotyping 34 single nucleotide polymorphisms (SNPs), we covered a total of 59 missense SNPs and SNPs located in the 5' and 3' untranslated regions (UTRs) of 10 different genes. Results: The Italian1 series showed a suggestive association for 8 SNPs, from which three were replicated in the Italian2 series. The meta-analysis revealed a study-wide significant association for rs459552 (OR: 0.84, 95%CI: 0.75–0.94) and rs1800900 (OR: 1.15, 95%CI: 1.05–1.27), located in the APC and GNAS genes, respectively. The APC rs459552 is a missense SNP, located in a conserved amino acid position, but without any functional consequences. The GNAS rs1800900 is located at a conserved 5'UTR and according to the experimental ENCODE data it may affect promoter and histone marks in different cell types. Conclusions: The results of this study yield new insights on WDTC, showing that inherited variants in the APC and GNAS genes can play a role in the etiology of thyroid cancer. Further studies are necessary to better understand the role of the identified SNPs in the development of WDTC and to functionally validate our in silico predictions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.
- Author
-
Pellé, Lucia, Cipollini, Monica, Tremmel, Roman, Romei, Cristina, Figlioli, Gisella, Gemignani, Federica, Melaiu, Ombretta, Santi, Chiara, Barone, Elisa, Elisei, Rossella, Seiser, Eric, Innocenti, Federico, Zanger, Ulrich, and Landi, Stefano
- Subjects
CYTOCHROME P-450 CYP2E1 ,GENETIC polymorphisms ,THYROID cancer ,ACRYLAMIDE ,GENOTYPES ,CANCER risk factors - Abstract
Differentiated thyroid carcinoma (DTC) results from complex interactions between genetic and environmental factors. Known etiological factors include exposure to ionizing radiations, previous thyroid diseases, and hormone factors. It has been speculated that dietary acrylamide (AA) formed in diverse foods following the Maillard's reaction could be a contributing factor for DTC in humans. Upon absorption, AA is biotransformed mainly by cytochrome P450 2E1 (CYP2E1) to glycidamide (GA). Considering that polymorphisms within CYP2E1 were found associated with endogenous levels of AA-Valine and GA-Valine hemoglobin adducts in humans, we raised the hypothesis that specific CYP2E1 genotypes could be associated with the risk of DTC. Analysis of four haplotype tagging SNPs (ht-SNPs) within the locus in a discovery case-control study ( N = 350/350) indicated an association between rs2480258 and DTC risk. This ht-SNP resides within a linkage disequilibrium block spanning intron VIII and the 3′-untranslated region. Extended analysis in a large replication set (2429 controls and 767 cases) confirmed the association, with odds ratios for GA and AA genotypes of 1.24 (95 % confidence interval (CI) 1.03-1.48) and 1.56 (95 % CI, 1.06-2.30), respectively. Functionally, the minor allele was associated with low levels of CYP2E1 mRNA and protein expression as well as lower enzymatic activity in a series of 149 human liver samples. Our data support the hypothesis that inter-individual differences in CYP2E1 activity could modulate the risk of developing DTC suggesting that the exposure to specific xenobiotics, such as AA, could play a role in this process. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Runs of homozygosity and inbreeding in thyroid cancer.
- Author
-
Thomsen, Hauke, Chen, Bowang, Figlioli, Gisella, Elisei, Rossella, Romei, Cristina, Cipollini, Monica, Cristaudo, Alfonso, Bambi, Franco, Hoffmann, Per, Herms, Stefan, Landi, Stefano, Hemminki, Kari, Gemignani, Federica, and Försti, Asta
- Subjects
COMPARATIVE studies ,CONSANGUINITY ,DISEASE susceptibility ,GENETIC polymorphisms ,GENETICS ,THYROID gland tumors ,SEQUENCE analysis ,GENOTYPES - Abstract
Background: Genome-wide association studies (GWASs) have identified several single-nucleotide polymorphisms (SNPs) influencing the risk of thyroid cancer (TC). Most cancer predisposition genes identified through GWASs function in a co-dominant manner, and studies have not found evidence for recessively functioning disease loci in TC. Our study examines whether homozygosity is associated with an increased risk of TC and searches for novel recessively acting disease loci.Methods: Data from a previously conducted GWAS were used for the estimation of the proportion of phenotypic variance explained by all common SNPs, the detection of runs of homozygosity (ROH) and the determination of inbreeding to unravel their influence on TC.Results: Inbreeding coefficients were significantly higher among cases than controls. Association on a SNP-by-SNP basis was controlled by using the false discovery rate at a level of q* < 0.05, with 34 SNPs representing true differences in homozygosity between cases and controls. The average size, the number and total length of ROHs per person were significantly higher in cases than in controls. A total of 16 recurrent ROHs of rather short length were identified although their association with TC risk was not significant at a genome-wide level. Several recurrent ROHs harbor genes associated with risk of TC. All of the ROHs showed significant evidence for natural selection (iHS, Fst, Fay and Wu's H).Conclusions: Our results support the existence of recessive alleles in TC susceptibility. Although regions of homozygosity were rather small, it might be possible that variants within these ROHs affect TC risk and may function in a recessive manner. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
44. Effects of radioiodine treatment for differentiated thyroid cancer on testis function.
- Author
-
Canale, Domenico, Ceccarelli, Claudia, Caglieresi, Carolina, Moscatelli, Agnese, Gavioli, Silvia, Santini, Pierina, Elisei, Rossella, and Vitti, Paolo
- Subjects
IODINE isotopes ,THYROID cancer ,TESTIS ,MALE reproductive organs ,OLIGOSPERMIA ,SPERM count - Abstract
Objective To evaluate the effects of radioactive iodine ( RAI) treatment for differentiated thyroid cancer ( DTC) on testis function. Design A prospective longitudinal single-centre study was performed. A comprehensive andrological evaluation including hormonal assessment, semen analysis and scrotal ultrasound was undertaken in male patients undergoing RAI treatment for DTC. Methods Hormonal assessment of FSH, LH, testosterone (T), sperm concentration and motility and testis volume were determined in 20 patients in basal conditions, 6 and 12 months after RAI. Results were analysed in the whole group of patients and then separately in those who received one single ablative treatment ('Single' group, n = 10) and those who received multiple treatments ('Multiple' group, n = 10). Results In basal conditions, 3 of 20 (15%) patients had a reduced sperm count and belonged to the 'Multiple' group. After RAI, an increase of FSH (8·8 ± 1·2 UI/l vs 5·2 ± 1·2, P < 0·005) and a decrease in sperm concentration (28·8 ± 7·7 millions/ml vs 54·5 ± 7·1, P < 0·005) and testis volume (15·2 ± 3·1 vs 13·7 ± 0·8 ml, P < 0·005) occurred at 6 months in the whole group. One year after RAI, seven patients had oligozoospermia (five from the 'Multiple' group and two from the 'Single' group). Permanent impairment of one or more testis function parameters was observed in patients who underwent multiple RAI treatments: 50% for sperm count, 40% for FSH levels and testis volume and, respectively, in 20 and 10% of those who received one single RAI treatment. Conclusions The single ablative RAI treatment in cancer patients is better tolerated respect multiple RAI treatments regard testis function. Multiple treatments for recurrent or metastatic disease may cause a permanent impairment of one or more parameters related to the reproductive potential of male patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma.
- Author
-
Sosa, Julie A., Elisei, Rossella, Jarzab, Barbara, Balkissoon, Jai, Lu, Shiao-ping, Bal, Chandrasekhar, Marur, Shanthi, Gramza, Ann, Yosef, Rami Ben, Gitlitz, Barbara, Haugen, Bryan R., Ondrey, Frank, Lu, Charles, Karandikar, S.M., Khuri, Fadlo, Licitra, Lisa, and Remick, Scot C.
- Subjects
- *
THYROID cancer , *PACLITAXEL , *CANCER invasiveness , *MEDICATION safety , *DRUG efficacy , *CANCER chemotherapy , *NEUTROPENIA , *RANDOMIZED controlled trials - Abstract
Background: Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel chemotherapy with or without fosbretabulin in patients with ATC. Methods: Patients were randomly assigned in a 2:1 ratio to 6 cycles of paclitaxel 200 mg/m2 followed by carboplatin AUC 6 on day 1 every 3 weeks (CP), or these drugs were given on day 2 after fosbretabulin 60 mg/m2 (CP/fosbretabulin) on days 1, 8 and 15. After 6 cycles, patients on the fosbretabulin arm without progression could continue to receive fosbretabulin on days 1 and 8 of a 3-week schedule until progression. The primary end point was overall survival (OS). Results: Eighty patients were assigned (planned, 180) when enrollment was stopped due to rarity of disease and very low accrual. Median OS was 5.2 months [95% confidence interval (CI) 3.1, 9.0] for the CP/fosbretabulin arm ( n=55; hazard ratio 0.73 [95% CI 0.44, 1.21]) and 4.0 months [95% CI 2.8, 6.2] for the CP arm ( n=25; p=0.22 [log rank test]). One-year survival for CP/fosbretabulin versus CP was 26% versus 9%, respectively. There was no significant difference in progression-free survival between the two arms. Grade 1-2 hypertension and grade 3-4 neutropenia were more common with CP/fosbretabulin. There were no significant adverse cardiovascular side effects. Conclusions: Although the study did not meet statistical significance in improvement in OS with the addition of fosbretabulin to carboplatin/paclitaxel, it represents the largest prospective randomized trial ever conducted in ATC. The regimen is well tolerated, with AEs and deaths primarily related to ATC and disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement.
- Author
-
Verburg, Frederik A., Luster, Markus, Cupini, Cristina, Chiovato, Luca, Duntas, Leonidas, Elisei, Rossella, Feldt-Rasmussen, Ulla, Rimmele, Harald, Seregni, Ettore, Smit, Johannes W.A., Theimer, Christian, and Giovanella, Luca
- Subjects
THYROGLOBULIN ,IMMUNOGLOBULINS ,THYROID cancer ,TUMOR markers ,THYROID cancer patients ,ALGORITHMS - Abstract
Background: Even though the presence of antithyroglobulin antibodies (TgAbs) represents a significant problem in the follow-up of patients with differentiated thyroid cancer (DTC), the current guidelines on the management of DTC that have been published in recent years contain no text concerning the methods to be used for detecting such antibody-related interference in thyroglobulin (Tg) measurement or how to manage TgAb-positive patients in whom Tg cannot be used reliably as a tumor marker. Aim: An international group of experts from the European Thyroid Association Cancer Research Network who are involved in the care of DTC patients met twice to form a consensus opinion on how to proceed with treatment and follow-up in TgAb-positive DTC patients based on the available evidence in the literature. Here we will report on the consensus opinions that were reached regarding technical and clinical issues. Results: This clinical opinion article provides an overview of the available evidence and the resulting consensus recommendations. The current literature does not provide sufficient data for giving evidence-based answers to many questions arising in the care of TgAb-positive DTC patients. Where insufficient evidence was available, a thorough discussion by a group of physician-scientists, all of whom have a distinguished track record in thyroid cancer care, was held to arrive at a consensus expert opinion. The questions and answers discussed were then summarized into an algorithm for the management of TgAb-positive patients. Conclusion: We were able to define 26 consensus expert recommendations and a resulting algorithm for the care of TgAb-positive DTC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
47. Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al.
- Author
-
Agate, Laura, Puleo, Luciana, Giani, Carlotta, Valerio, Laura, Molinaro, Eleonora, and Elisei, Rossella
- Subjects
THYROID cancer ,CHOLECYSTITIS ,CANCER treatment - Abstract
B Dear Editor: b Recently, Nervo I et al. i ([1]) presented the results of their retrospective analysis of 36 patients treated with lenvatinib for advanced radioactive iodine (RAI) refractory (RAI-R) differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC) from June 2012 to December 2018. This letter is for supporting the findings of Nervo I et al. i since we also observed this type of AE in our series of 84 RAI-R DTC/PDTC patients who were treated with lenvatinib from February 2012 to September 2018. Our data are comparable with those of Nervo I et al. i and confirm that overall, pulling together the 2 series, GB/BD are present in 16 of 118 (13.5%) of patients treated with lenvatinib. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
48. Association Between BRAFV6OOE Mutation and Mortality in Patients With Papillary Thyroid Cancer.
- Author
-
Mingzhao Xing, Alzahrani, Ali S., Carson, Kathryn A., Viola, David, Elisei, Rossella, Bendlova, Bela, Yip, Linwah, Mian, Caterina, Vianello, Federica, Tuttle, R. Michael, Robenshtok, Eyal, Fagin, James A., Puxeddu, Efisio, Fugazzola, Laura, Czarniecka, Agnieszka, Jarzab, Barbara, O'Neill, Christine J., Sywak, Mark S., Lam, Alfred K., and Riesco-Eizaguirre, Garcilaso
- Subjects
GENETIC mutation ,THYROID cancer ,CANCER-related mortality ,ONCOGENES ,DEATH rate ,PATHOLOGICAL physiology ,GENETICS - Abstract
The article discusses research which investigated the relationship between BRAF V600E mutation and papillary thyroid cancer (PTC)-related mortality. BRAF V600E is a prominent oncogene in PTC. A total of 1,849 patients with a median age of 46 years are considered in the study. Findings revealed 5.3% mortality in BRAF-positive versus mutation-negative patients. Deaths per 1000 person-years in the analysis of PTC conventional variant were 11.80 versus 2.25 in BRAF-positive versus mutation-negative patients. A higher BRAF-associated mortality was observed in clinicopathological subcategories.
- Published
- 2013
- Full Text
- View/download PDF
49. Incidental versus clinically evident thyroid cancer: A 5-year follow-up study.
- Author
-
Minuto, Michele N., Miccoli, Mario, Viola, David, Ugolini, Clara, Giannini, Riccardo, Torregrossa, Liborio, Antonangeli, Lucia, Aghini‐Lombardi, Fabrizio, Elisei, Rossella, Basolo, Fulvio, and Miccoli, Paolo
- Subjects
THYROID cancer ,FOLLOW-up studies (Medicine) ,PREOPERATIVE period ,THYROIDECTOMY ,COMPARATIVE studies - Abstract
Background The incidence of differentiated thyroid cancer in patients undergoing surgery for presumed benign thyroid disease (incidental thyroid cancer) is not negligible. The purpose of this study was to verify if incidental thyroid cancers have a different clinical course than the clinically evident thyroid cancer. Methods A group of patients with incidental thyroid cancer ( n = 95) has been compared to a control group with clinically evident thyroid cancer ( n = 93). Both the histology and the outcome after a 5-year follow-up have been compared. Results At the univariate analysis, the groups demonstrated significant differences in many pathologic features, remnant ablation ( p < .001), and persistent disease ( p = .006). Nevertheless, the multivariate analysis revealed that the outcome was not influenced by the preoperative or the incidental diagnosis. Conclusion Incidental thyroid cancers show a different pathological pattern when compared to clinically evident thyroid cancers. Nonetheless, the final outcome is not influenced by preoperative or postoperative diagnosis. Hence, patients with incidental thyroid cancer should follow the same postoperative protocols of patients with clinically evident thyroid cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2013 [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
50. Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series.
- Author
-
Ciampi, Raffaele, Mian, Caterina, Fugazzola, Laura, Cosci, Barbara, Romei, Cristina, Barollo, Susi, Cirello, Valentina, Bottici, Valeria, Marconcini, Giulia, Rosa, Pelizzo Maria, Borrello, Maria Grazia, Basolo, Fulvio, Ugolini, Clara, Materazzi, Gabriele, Pinchera, Aldo, and Elisei, Rossella
- Subjects
DISEASE prevalence ,THYROID cancer ,GENETIC mutation ,META-analysis ,RAS oncogenes ,HISTOPATHOLOGY - Abstract
Background: Approximately 60% of sporadic medullary thyroid carcinomas (sMTC) remain orphan of a recognized genetic cause. Recently, a high percentage of RAS point mutations have been described in RET-negative sMTC. The aim of this study was to assess the prevalence of RAS point mutations in a large series of MTC collected in four Italian centers. Methods: For this purpose, we studied codons 12, 13, and 61 of H-, K-, and N- RAS genes in 188 MTC samples, either hereditary or sporadic, by direct sequencing. Correlations between the RAS mutational status and the clinical-pathological features of MTC patients as well as a meta-analysis of all published data were performed. Results: The prevalence of RAS mutations in the present series of MTC was 10.1%, and 17.6% when considering only RET-negative cases. RAS mutations were found in MTC tumoral tissue, but not in peripheral blood indicating their somatic origin. A novel mutation in codon 72 (M72I) was found, but with a low or null transforming potential. No association was found between the presence of RAS mutations and the clinical-pathological features of the patients. Although not statistically significant, a positive association between the presence of RAS mutations and a better outcome was observed. The meta-analysis of all published studies confirmed a prevalence of 8.8% for RAS mutations in MTC. Conclusions: The prevalence of RAS mutations in our MTC series was relatively low and consistent with the meta-analysis data. Only somatic RAS mutations were found and only in RET-negative sMTC. Likewise, MTCs that harbor a RAS mutation identify a subgroup of tumors with less aggressive behavior. To our knowledge, this is the largest series of MTCs studied for the presence of mutations in RAS genes and the first meta-analysis on this specific topic. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.